In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Akero Therapeutics Inc’s stock clocked out at $42.17, up 2.85% from its previous closing price of $41.00. In other words, the price has increased by $2.85 from its previous closing price. On the day, 1.41 million shares were traded. AKRO stock price reached its highest trading level at $42.43 during the session, while it also had its lowest trading level at $41.119.
Ratios:
To gain a deeper understanding of AKRO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 19.38 and its Current Ratio is at 19.38. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on January 30, 2025, Upgraded its rating to Buy and sets its target price to $63 from $35 previously.
On January 27, 2025, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $50 to $72.
On November 18, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $65.Citigroup initiated its Buy rating on November 18, 2024, with a $65 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 24 ’25 when Rolph Timothy sold 6,250 shares for $41.03 per share. The transaction valued at 256,438 led to the insider holds 169,721 shares of the business.
Yale Catriona sold 9,073 shares of AKRO for $343,962 on Apr 15 ’25. The Chief Development Officer now owns 95,034 shares after completing the transaction at $37.91 per share. On Apr 10 ’25, another insider, Cheng Andrew, who serves as the President and CEO of the company, sold 30,000 shares for $35.23 each. As a result, the insider received 1,056,780 and left with 624,324 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 3357579264 and an Enterprise Value of 2650619904.
Stock Price History:
The Beta on a monthly basis for AKRO is -0.11, which has changed by 1.1201608 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, AKRO has reached a high of $58.40, while it has fallen to a 52-week low of $17.86. The 50-Day Moving Average of the stock is -1.71%, while the 200-Day Moving Average is calculated to be 25.55%.
Shares Statistics:
It appears that AKRO traded 1.44M shares on average per day over the past three months and 1018080 shares per day over the past ten days. A total of 72.38M shares are outstanding, with a floating share count of 70.71M. Insiders hold about 11.19% of the company’s shares, while institutions hold 87.36% stake in the company. Shares short for AKRO as of 1744675200 were 6308848 with a Short Ratio of 4.39, compared to 1741910400 on 5203442. Therefore, it implies a Short% of Shares Outstanding of 6308848 and a Short% of Float of 8.129999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
